|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08189 TEDA BIOMEDICAL
Nominal 
0.260 0.000 (0.000%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 296,035 | 30.753% | 522,967 | 385,482 | 397,998 | 449,676 |
| Cost of Sales | (262,672) | 23.560% | (487,292) | (365,259) | (376,632) | (433,281) |
| Gross Profit | 33,363 | 141.397% | 35,675 | 20,223 | 21,366 | 16,395 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (18,740) | (2,409) | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (87,069) | (1,109) | (1,707) | (315) | |
| Profit / (Loss) on Disposal | -- | -- | (8,216) | -- | -- | 5,912 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | (3) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 15,322 | -- | (112,936) | (38,207) | (12,012) | (26,495) | |
| Taxation | (440) | -- | (609) | 221 | 1,044 | (151) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | 1,846 | (5,602) | -- | |
| Non-controlling Interests | (4,674) | -- | 22,724 | 8,337 | (3,589) | (1,460) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 10,208 | -- | (90,820) | (27,802) | (20,160) | (28,106) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,534 | -22.297% | 3,711 | 4,533 | 4,923 | 5,639 |
| Depreciation & Amortisation | -- | -- | 9,492 | 9,128 | 10,945 | 15,390 |
| Directors' Emoluments | -- | -- | -- | 876 | 1,120 | 1,387 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified | Unqualified (Modified Report) | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 0.048 | -- | -4.370 | -1.460 | -1.060 | -1.480 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.026) | (0.014) | (0.007) | (0.007) |
| NBV per share ($) | 0.011 | -- | 0.006 | 0.012 | 0.026 | 0.037 |
| Remarks: | Real time quote last updated: 15/09/2026 17:55 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 10,208 |
| %Change | -- |
| EPS / (LPS) | RMB 0.000 |
| NBV Per Share (¥) | RMB 0.011 |